levomepromazine

Trade name: levoprome

Small moleculeapproved

Levomepromazine (also known as methotrimeprazine) is a phenothiazine neuroleptic drug. It is sold in many countries under the generic name (levomepromazine) or under brand names such as Nozinan, Detenler and many more. Levomepromazine is an antipsychotic drug is commonly used as an antiemetic to alleviate nausea and vomiting in palliative care settings particularly in terminal illness. Levomepromazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. Levomepromazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, it can block 5HT2 receptors and some others, like histamine, serotonin. — NCATS

Clinical trial activity

4 trials · 5 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 1, 2011 (NCT01323205)

Timeline

1960s

Jun 1, 1966
American Cyanamid — First NDA Organization
Jun 1, 1966
American Cyanamid — NDA Organization

2010s

Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Jan 1, 2012
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

D2-like dopamine receptorANTAGONIST
D2-like dopamine receptor antagonist

Approval history

approved—

Chemistry & pharmacology

Loading structure…

SMILES

COC1=CC=C2SC3=CC=CC=C3N(C[C@H](C)CN(C)C)C2=C1

Mol. weight: 328.472 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Availability: Discontinued

Oral

Parenteral

Topical

Sources

Also known as

(-)-10-(3-(dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine
(-)-10-(3-(dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine
2-methoxytrimeprazine
2-methoxytrimeprazine
(-)-(2r)-3-(2-methoxy-10h-phenothiazin-10-yl)-n,n,2-trimethylpropan-1-amine
(-)-(2r)-3-(2-methoxy-10h-phenothiazin-10-yl)-n,n,2-trimethylpropan-1-amine
cl-36467
cl-36467
cl-39743
cl-39743
hirnamin
levinan
levomeprazine
levomepromazin
levomepromazina
levomepromazina
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine
levomepromazine hcl
levomepromazine hcl
levomepromazine hydrochloride
levomepromazine hydrochloride
levomepromazine maleate
levomepromazine maleate
levomepromazine maleate
levomepromazinum
levomepromazinum
levopromazine
levoprome
levoprome
levoprome
levoprome
levopromethazine
levotomin
mepromazine
methotrimeprazine
methotrimeprazine
methotrimeprazine
methotrimeprazine
methotrimeprazine
methotrimeprazine
methotrimeprazine hydrochloride
nirvan
nirvan
nozinan
nozinan
nozinan
nozinan
rp-7044
rp-7044
sk&f-5116
sk&f-5116
tisercin
tisercin
veractil
veractil
xp03
xp03

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02009306	Phase 4	Jan 23, 2017	Gloucestershire Hospitals NHS Foundation Trust
NCT02374567	Phase 3	Jan 1, 2015	Gottfried Wilhelm Leibniz Universität Hannover
NCT01765829	Phase 3	Nov 1, 2012	Government of Spain, Universidad Carlos III Madrid
NCT01323205	Phase 2	May 1, 2011	Johnson and Johnson

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (5)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Gloucestershire Hospitals NHS Foundation Trust	Academic/Hospital	1	1	1	2017
Gottfried Wilhelm Leibniz Universität Hannover	Academic/Hospital	1	1	1	2015
Government of Spain	Government	1	1	1	2012
Johnson and Johnson	For profit	1	1	1	2011
Universidad Carlos III Madrid	Academic/Hospital	1	0	1	2012

5 organizations

Page 1 / 1

Marketing (2)

Organization	Org type	Relationship	Date
American Cyanamid	For profit	NDA	Jun 1, 1966
Immunex	For profit	NDA2	—